Skip to content

Processa Pharmaceuticals, Inc.: 10-Q filed 2026-08-14

What Processa Pharmaceuticals, Inc. reported in its quarterly report filed 2026-08-14 (fiscal Q2 2026): 29 published measures, 81 facts as tagged in accession 0001493152-26-038334.

This filing

Form
10-Q (quarterly report)
Filed
2026-08-14
Fiscal period
fiscal Q2 2026
Accession
0001493152-26-038334 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Processa Pharmaceuticals, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2026-06-302,069,562USD
At 2025-12-317,813,567USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2026-06-302,386,903USD
At 2025-12-312,236,253USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2026-06-30-317,341USD
At 2026-03-312,540,881USD
At 2025-12-315,577,314USD
At 2025-06-306,107,208USD
At 2025-03-313,526,608USD
At 2024-12-311,696,171USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2026-06-30196,325USD
At 2025-12-315,536,955USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-3,265,494USD91
2026-01-01 to 2026-06-30-6,642,673USD181
2026-01-01 to 2026-03-31-3,377,179USD90
2025-04-01 to 2025-06-30-3,933,918USD91
2025-01-01 to 2025-06-30-6,768,323USD181
2025-01-01 to 2025-03-31-2,834,405USD90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2026-01-01 to 2026-06-30-5,586,580USD181
2025-01-01 to 2025-06-30-5,000,253USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2026-01-01 to 2026-06-30559,950USD181
2025-01-01 to 2025-06-3010,745,548USD181

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2026-01-01 to 2026-06-30-314,000USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2026-06-30-107,425,706USD
At 2025-12-31-100,783,033USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2026-04-01 to 2026-06-302,750,742shares91
2026-01-01 to 2026-06-302,687,295shares181
2025-04-01 to 2025-06-30628,796shares91
2025-01-01 to 2025-06-30502,085shares181

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2026-04-01 to 2026-06-302,750,742shares91
2026-01-01 to 2026-06-302,687,295shares181
2025-04-01 to 2025-06-30628,796shares91
2025-01-01 to 2025-06-30502,085shares181

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-1.19USD/shares91
2026-01-01 to 2026-06-30-2.47USD/shares181
2025-04-01 to 2025-06-30-6.26USD/shares91
2025-01-01 to 2025-06-30-13.48USD/shares181

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-1.19USD/shares91
2026-01-01 to 2026-06-30-2.47USD/shares181
2025-04-01 to 2025-06-30-6.26USD/shares91
2025-01-01 to 2025-06-30-13.48USD/shares181

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2026-06-303,210USD
At 2025-12-313,812USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2026-01-01 to 2026-06-30188,068USD181
2025-01-01 to 2025-06-30430,962USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-2,336,138USD91
2026-01-01 to 2026-06-30-5,667,352USD181
2025-04-01 to 2025-06-30-3,950,783USD91
2025-01-01 to 2025-06-30-6,797,773USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2026-06-302,066,352USD
At 2025-12-315,670,874USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2026-06-302,386,903USD
At 2025-12-312,236,253USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2026-06-301,659,438USD
At 2025-12-311,056,796USD

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2026-06-302,793,386shares
At 2025-12-312,571,914shares

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2026-06-30727,465USD
At 2025-12-311,179,457USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2026-06-301,398,024USD
At 2025-12-31133,919USD

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-3,265,494USD91
2026-01-01 to 2026-06-30-6,642,673USD181
2025-04-01 to 2025-06-30-3,933,918USD91
2025-01-01 to 2025-06-30-6,768,323USD181

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2026-04-01 to 2026-06-301,686,261USD91
2026-01-01 to 2026-06-303,208,311USD181
2025-04-01 to 2025-06-301,503,497USD91
2025-01-01 to 2025-06-302,762,006USD181

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2026-01-01 to 2026-06-30602USD181
2025-01-01 to 2025-06-30602USD181

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-929,356USD91
2026-01-01 to 2026-06-30-975,321USD181
2025-04-01 to 2025-06-3016,865USD91
2025-01-01 to 2025-06-3029,450USD181

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2026-01-01 to 2026-06-3010,325USD181
2025-01-01 to 2025-06-301,880USD181

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2026-01-01 to 2026-06-30560,270USD181
2025-01-01 to 2025-06-3010,758,802USD181

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2026-01-01 to 2026-06-30602,642USD181
2025-01-01 to 2025-06-30-95,126USD181

Inspect the source

Entity
Processa Pharmaceuticals, Inc. / CIK 0001533743
Captured
2026-09-20T09:16:31.348Z
SEC response SHA-256
5f3216d9024f2a7fc94b315f5bf243c7efb048273a6be394a2f74186d7af2a31

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001533743.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))